NovMetaPharma Co., Ltd. (XKON:229500)

Market Cap	151.50B
Revenue (ttm)	1.30B +21.4%
Net Income	408.03M
EPS	120.00
Shares Out	12.71M
PE Ratio	99.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,312
Average Volume	5,710
Open	12,000
Previous Close	12,000
Day's Range	11,580 - 12,470
52-Week Range	4,810 - 17,890
Beta	0.39
RSI	36.72
Earnings Date	n/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic and fibrotic diseases in South Korea. It is developing Cyclo-Z, which is in phase 2 clinical stage; and CHP that is in phase 1 clinical stage for the treatment of diabetic kidney disease, obesity, and rare conditions, including FSHD and DMD. The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015. NovMetaPharma Co., Ltd. was incorporated in 2010 and is headquartered in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 229500